Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
Primary Purpose
Neoplasm, Lymphomas, Neoplasm Metastasis
Status
Terminated
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
PEG-paclitaxel
Sponsored by
About this trial
This is an interventional treatment trial for Neoplasm focused on measuring Phase I, Open label, Safety/efficacy, Lymphomas, Advanced primary and/or metastatic solid tumors, Neoplasms, Neoplasm metastasis
Eligibility Criteria
None - Study has been terminated.
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00023166
First Posted
August 24, 2001
Last Updated
June 23, 2005
Sponsor
Enzon Pharmaceuticals, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00023166
Brief Title
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
Official Title
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas
Study Type
Interventional
2. Study Status
Record Verification Date
March 2004
Overall Recruitment Status
Terminated
Study Start Date
May 2001 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
May 2002 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Enzon Pharmaceuticals, Inc.
4. Oversight
5. Study Description
Brief Summary
Studies of PEG-paclitaxel have been terminated
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neoplasm, Lymphomas, Neoplasm Metastasis
Keywords
Phase I, Open label, Safety/efficacy, Lymphomas, Advanced primary and/or metastatic solid tumors, Neoplasms, Neoplasm metastasis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
PEG-paclitaxel
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
None - Study has been terminated.
12. IPD Sharing Statement
Learn more about this trial
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
We'll reach out to this number within 24 hrs